Scaling the Science
In this edition of the Smart Investor newsletter, we spotlight a core operator of modern diagnostic and life sciences infrastructure. But first, let’s review the latest Smart Portfolio developments.
1
Portfolio News and Updates
❖❖ President Donald Trump has filed a $5 billion lawsuit in Florida state court against JPMorgan Chase (JPM) and its CEO Jamie Dimon, alleging politically motivated debanking in early 2021. The bank issued a statement saying the lawsuit has “no merit” and that it never closed accounts for political or religious reasons. The bank claimed that it only closes accounts when they pose legal or regulatory risk, and it has long advocated for a change to the so-called “reputational risk” guidelines, which were viewed as vague and subjective. Federal regulators said they would stop policing banks on these standards last year.
1
❖❖ Microsoft (MSFT) saw its price target reduced by several analysts going into earnings. Street consensus is built around expectations of continued strong earnings growth, powered by AI-driven demand for its Azure cloud business – supported by new AI data centers – and accelerating incorporation of the advanced tech across the company’s offerings. However, analysts cited industry-wide multiple compression in software and valuation worries around AI as the reasons for PT decreases, rather than weaker fundamentals at MSFT. Despite the cuts, analysts see a potential average upside of about 34% for the stock, based on cloud strength, massive backlog, rollout of new AI features, and reinvigorated gaming pipelines.
❖ Meanwhile, MSFT made an important announcement on Monday, launching Maia 200 – its second-generation custom AI accelerator chip designed specifically for AI inference. Built on TSMC’s (TSM) advanced 3nm process, the chip displays the best performance among first-party silicon from any hyperscaler. Maia 200 is already being deployed in Azure data centers, starting in Iowa. The inference-focused powerhouse chip supports massive clusters via standard Ethernet – up to 6,144 accelerators – avoiding proprietary interconnects like Nvidia’s NVLink, thus lowering costs and easing scaling for hyperscale clouds.
Currently, Microsoft – along with other hyperscalers – relies heavily on Nvidia GPUs for AI. By building and scaling its own chips, MSFT gains cost control, supply-chain independence, and easier customization for Azure needs. This is part of the broader custom silicon trend, following Google’s (GOOGL) and Amazon’s (AMZN) latest in-house designs that challenge Nvidia’s dominance. While Nvidia still heavily dominates training, inference now represents the lion’s share of AI costs, as models deploy widely, making custom silicon all the more important. It’s not only that Maia 200’s efficiency could accelerate adoption of larger models and more AI features in products, but it should also drive better margins on Azure AI services, Copilot, and the OpenAI partnership. Moreover, it strengthens Azure’s competitiveness vs. AWS and Google Cloud.
The announcement is a strong positive for related hardware and infrastructure companies, including several Smart Portfolio holdings. TSMC – the world’s leading AI-chip foundry – is a direct winner, of course, with MSFT’s advance reinforcing its custom-chip dominance. Arista Networks (ANET) stands out as a key beneficiary of Microsoft’s emphasis on Ethernet-based networking for large clusters due to its specialization in high-performance Ethernet switches and routers for data centers, especially AI-scale fabrics. Broadcom (AVGO), while not the primary partner for ASICs and interconnects in Maia 200 development (that’s Marvell in this case), is widely seen as a potential beneficiary. AVGO supplies high-speed interconnects and optics critical for large Ethernet-based AI clusters, with Microsoft’s emphasis on commodity Ethernet versus proprietary fabrics favoring Broadcom’s expertise in the optics space.
❖ In other news, Microsoft has received preliminary approval for a massive $13.3 billion expansion in Mount Pleasant, Wisconsin, representing a major step in the tech giant’s AI infrastructure push. The company is planning to add two new data center campuses covering over 1,300 acres and offering over 8.7 million square feet of facility space. When combined with Microsoft’s already approved or under-construction projects in the same area, the total campus could eventually exceed $20 billion and cover roughly 2,000 acres, making it one of the largest data center developments in the U.S. This move underscores MSFT’s multi-billion-dollar bet on AI infrastructure. While Microsoft’s and other hyperscalers’ – including Smart Portfolio holdings Alphabet (GOOGL) and Amazon (AMZN) – massive AI infrastructure and hardware-related capex is essential to remain competitive in the AI race, this may temporarily limit their profitability in 2026 due to lagging economic absorption (i.e., delayed returns on investment).
❖ While return on the hundreds of billions in current AI capex could look disappointing in the near term for shareholders of hyperscalers and other heavy spenders, it is expected to continue being a boon for infrastructure, hardware, and other “picks and shovels” plays along the AI value chain. For example, high-speed networking gear provider Arista Networks (ANET) – with about 20% of revenue tied to MSFT – is one of the key beneficiaries. Others include Vertiv Holdings (VRT), which provides critical power, cooling, and thermal management for data centers; Sterling Infrastructure (STRL), specializing in e-infrastructure, site prep, utilities, and civil construction for data centers; MasTec (MTZ), which provides power, communications, and infrastructure construction projects; and other Smart Portfolio holdings.
❖ In yet other news, Microsoft officially announced Rho-alpha (ρα), its first robotics AI model, based on the company’s vision-language-action (VLA+) foundation model incorporating vision, language understanding, and tactile sensing. VLA+ models are specifically designed for robotic manipulation, translating natural language commands into precise control signals for robots. MSFT positions it as a research milestone toward practical, embodied AI. As such, Rho-alpha represents a step toward advancing “physical AI” – AI systems that can interact effectively with the real world – which is seen as a key next phase in AI development, bridging semantic reasoning with physical actions. The announcement drew praise from analysts and investors who believe it further reinforces Microsoft’s edge in AI innovation and expands its ecosystem, while adding significant potential revenue streams in areas like manufacturing, healthcare, and consumer robotics.
❖ MSFT is joining Alphabet’s (GOOGL) Google in this race, which began to draw serious attention after the legendary AI guru and DeepMind CEO Demis Hassabis stated that robotics is “on the cusp of a breakthrough moment” for physical AI. In early January, GOOGL announced that DeepMind is integrating Gemini Robotics models into Boston Dynamics’ humanoid robot Atlas, combining Google’s generative AI capabilities with Boston Dynamics’ industry-leading robotic hardware. Google is positioning this as a key step toward practical, real-world AI agents.
1
❖❖ In contrast to Microsoft, Alphabet (GOOGL) has seen strictly positive analyst action in recent weeks, with price-target upgrades continuing to arrive going into earnings. On Monday, KeyBanc hiked its PT to $360 from $330, citing benefits from AI product cycles. This follows a rating upgrade by Raymond James – from “Buy” to “Strong Buy” – with the price target raised from $315 to a Street-high of $400. The firms said that within a relatively short period, GOOGL transformed itself from an AI laggard to an AI leader, with material upward revisions to 2026/27 revenue estimates driven by improved AI credentials across GCP and Search, including Gemini and AI-powered features. Roth MKM also raised its PT – from $310 to $365 – citing custom silicon partnerships, Waymo city launches, Gemini App user milestones, and likely Gemini 4.0 news as key catalysts.
❖ Meanwhile, Google announced that it has acquired an AI startup, Common Sense Machines (CSM), founded in 2020 and valued at $15 million. CSM’s core technology excels at converting 2D inputs – such as 2D images or text – into detailed, usable 3D digital objects with geometry, textures, and structure. This aligns with Google’s push into spatial AI, the next major frontier in artificial intelligence relating to machines’ ability to perceive, model, navigate, and manipulate three-dimensional space. Spatial AI is a critical foundation for physical AI, since in order to act intelligently in the physical world, a robot must first understand 3D space. As such, CSM capabilities – which are being folded into Google DeepMind – can notably accelerate advancements in robotic/physical AI, 3D generation, and multimodal AI.
1
❖❖ Credo Technology (CRDO) saw a notable decline last week, primarily driven by profit taking after the stock’s massive prior gains and concerns over its elevated valuation amid broader sector volatility. Despite some hesitation – such as Rosenblatt’s “Hold” rating with a Street-low $170 target – analyst sentiment remains largely positive, with a consensus “Strong Buy” rating and the average price target implying over 75% upside.
Recent updates reinforce the bull case: Barclays raised its price target to $260 – the highest on the Street – citing strong AI-driven semiconductor demand in 2026, while Needham added CRDO to its Conviction List and named it a Top Pick for the year. Bank of America recently addressed valuation concerns, highlighting CRDO’s attractive forward PEG ratio of around 0.6x amid expectations of ~170% revenue growth for FY2026, fueled by surging AI infrastructure spending.
Moreover, Microsoft’s recent announcements are highly positive for CRDO – a key supplier of reliable, efficient connectivity solutions to long-standing hyperscaler customers, including MSFT. Both the rollout of Maia 200 and the Mount Pleasant campus expansion align directly with Credo’s core strengths in high-speed Active Electrical Cables (AECs). MSFT’s shift to Ethernet interconnects in Maia 200 clusters plays squarely into CRDO’s expertise – offering better power efficiency and cost than passive cables or optics for rack-scale AI deployments.
1
❖❖ GE Aerospace (GE) beat analyst estimates on top and bottom lines in Q4, clocking in 20% adjusted revenue increase year-over-year – with both operating segments delivering double-digit growth – and a 19% jump in adjusted EPS. Free cash flow expanded 15%, with cash conversion above 100%, and operating profit up 14%.
These results wrapped up an excellent year, with revenue up 21% and orders surging 32%, while backlog reached roughly $190 billion – up nearly $20 billion year over year – providing multi-year revenue visibility. The company achieved $10 billion in operating profit – which surged 25% for the full year – two years ahead of original projections. Full-year adjusted EPS soared 38% to $6.37, driven by operating profit improvement and a lower tax rate. 2026 guidance signaled continued growth: GE expects low double-digit revenue growth, operating profit of $9.85-10.25 billion (up $1 billion at midpoint), and EPS of $7.10-7.40 (up nearly 15%). Free cash flow is projected at $8.0-8.4 billion with conversion remaining well above 100%.
1
❖❖ RTX (RTX) posted a blowout Q4, driven by higher sales from ongoing demand for munitions and missiles. Fourth-quarter sales climbed 12% year-over-year to $24.2 billion – exceeding analyst expectations of $22.7 billion – with strong execution across segments. The company’s backlog soared to $268 billion, including $161 billion commercial and $107 billion defense. Adjusted EPS of $1.55 surged past analyst estimates of $1.47. Operating cash flow reached $4.2 billion in the quarter, while free cash flow hit $3.2 billion – sharply higher than a year earlier.
The company offered an upbeat FY 2026 outlook, forecasting adjusted sales of $92.0-93.0 billion, adjusted EPS of $6.60-6.80, and free cash flow of $8.25-8.75 billion. RTX’s robust guidance reflects strong backlog conversion, continued investment in production capacity and new capabilities, and favorable positioning amid President Trump’s increased emphasis on defense spending – alongside heightened geopolitical tensions – which analysts expect to support ongoing growth in defense initiatives and commercial aerospace involvement.
1
1
Portfolio Stocks Under Review
❖ We are keeping Oracle (ORCL) in our “Under Review” bracket, planning to watch it closely until its next earnings report in mid-March. While we still hold a strong conviction about the company’s prospects in the medium to long term, the near-term ride may prove wild enough to shake our will to hold on to ORCL stock. On the other hand, there are factors in play that could further confirm our positive outlook.
Oracle’s fiscal Q2 2026 was a mixed bag, with a solid bottom-line growth even after stripping the one-off items, and a strong top-line expansion. Cloud revenue jumped 33% year-over-year, while cloud-infrastructure sales soared 66%, driven by a 177% surge in GPU-related sales – but these eye-popping results still came below overheated expectations. Even a 433% surge in RPOs hasn’t done much to improve sentiment, as investors were already questioning Oracle’s ability to translate backlog into near-term revenue. Another issue in question is Oracle’s reliance on OpenAI, which constitutes about 60% of its RPO, coupled with worries over the AI startup’s ability to pay these staggering sums.
Meanwhile, Oracle’s capex projections were higher than expected, and deeper-than-anticipated free-cash-flow pressures meant that the elevated capex needed to be financed through debt. With liabilities rising nearly as fast as doubts about ORCL’s ability to convert orders on the books into real hard cash, it is no wonder that sentiment sank. Oracle has come under more pressure after bondholders filed a proposed class-action lawsuit alleging it didn’t fully disclose the scale of additional debt it would seek to fund its AI infrastructure build-out.
While some of the existing worries surrounding Oracle have begun to lessen, this is far from an “all clear” setup. The sentiment regarding AI supply-chain components – including ORCL – is volatile, with investors selling off the broad theme one day, just to soar in the next. TSMC’s (TSM) blockbuster outlook and Nvidia boss’s pointing to infrastructure and hardware as some of the key bottlenecks certainly add to ORCL’s appeal. So did the projections of global AI spending reaching $2.53 trillion in 2026 and $3.33 trillion in 2027, with the bulk of that going to AI infrastructure, including OCI – a major player in providing the compute, storage, networking, and data center capacity needed to power AI workloads.
The TikTok deal is also a major win for the company – providing long-term revenue visibility through a high-margin, sticky, big-ticket contract, and confirming OCI as a key player in AI/cloud infrastructure. With TikTok’s U.S. operations required to store all U.S. user data on OCI, analysts estimate ORCL could generate $10-20 billion, or even more, in cumulative revenue over the next 5-10 years from this business alone. This deal also validates Oracle as the fourth hyperscaler, as well as a sovereign and secure cloud play. This validation was further strengthened by recent Services Group research, which found that U.S. enterprises are increasingly adopting OCI as part of a broader shift toward multicloud strategies powered by data, AI, and the need for better business agility.
The question of the backlog’s heavy reliance on OpenAI is also being addressed through large partnerships. Meta has recently announced a major new strategic initiative, Meta Compute, focused on building and scaling massive AI infrastructure – and aggressively supplementing its own capacity with third-party cloud providers. OCI plays a major role in this push through a large multi-year cloud computing agreement with Meta, potentially worth around $20 billion – and coming on top of the already existing AI training and compute collaboration. In 2025, Oracle struck multi-billion-dollar contracts with other key industry players, which analysts believe are xAI, Nvidia, and AMD.
However, concerns about mounting capital requirements remain in place. The question about ORCL’s ability to post EPS growth in line with its 2026 and 2027 targets – let alone surpass them – led Morgan Stanley’s analysts to slash the company’s price target by over 30% to $213. However, the Street targets differ wildly – ranging from $180 at D.A. Davidson to $400 at Guggenheim and Mizuho, underscoring the overwhelming uncertainty regarding Oracle’s debt-fueled AI infrastructure buildout.
All in all, 2026 is expected to be the “show me the money” year for Oracle. In its fiscal Q3 2026, we expect to gain a meaningful signal about the company’s ability to convert RPO into cash, as its near-term investment case strongly hinges on execution.
1
1
Portfolio Earnings and Dividend Calendar
❖ The Q4 2025 earnings season is in full swing, and several Smart Portfolio holdings are expected to report over the next week. General Dynamics (GD), Amphenol (APH), Microsoft (MSFT), and IBM (IBM) will report today, and Parker Hannifin (PH) – tomorrow. Pfizer (PFE) and ATI (ATI) will release their results on February 3, while Alphabet (GOOGL) and Boston Scientific (BSX) are scheduled to report on February 4.
❖ The ex-dividend date for Morgan Stanley (MS) is January 30, while for Citigroup (C) it is February 2.
w
1
New Buy: Labcorp Holdings (LH)
Labcorp Holdings Inc. is a major global provider of life sciences and diagnostics, sitting at the center of the modern healthcare system and operating as a critical intermediary between physicians, health systems, life sciences companies, and patients. The company provides diagnostic testing and clinical laboratory services that underpin routine care, disease detection, and treatment decisions, while also supporting pharmaceutical and biotechnology development through its contract research and drug development operations. LH’s reach spans clinical diagnostics, precision medicine, and outsourced clinical trials, positioning it as both a healthcare service provider and a life sciences enabler. Often operating behind the scenes, the company functions as essential infrastructure – translating biological data into actionable medical insight and accelerating the path from research to real-world patient care.
1
Testing the System
Labcorp’s roots trace back to 1971, when it was founded as a regional laboratory business focused on providing physicians with reliable, standardized diagnostic testing. Over the following decades, the company expanded steadily through a combination of organic growth and acquisitions, building national scale in a fragmented laboratory market. A defining early transformation came in the 1990s and early 2000s, when Labcorp invested heavily in automation, logistics, and informatics – moves that allowed it to consolidate smaller laboratories and establish itself as one of the dominant players in U.S. diagnostics.
The company’s most consequential strategic shift arrived in 2015 with the acquisition of Covance, a leading contract research organization. That transaction fundamentally broadened Labcorp’s identity, extending its role beyond diagnostics into pharmaceutical and biotechnology development. At the time, the strategy was explicitly integrative: rather than operating as a collection of standalone services, LH sought to connect clinical testing, clinical trials, and post-approval data into a single life sciences platform. This approach positioned the company as a bridge between laboratory insight and drug development execution, spanning discovery, trials, and real-world application.
Over the past five years, Labcorp’s evolution has accelerated. The COVID-19 pandemic underscored the strategic value of large-scale laboratory infrastructure, but management used the period to do more than absorb volume. Investments in automation, digital reporting, and data analytics improved throughput and reliability while reinforcing relationships with health systems, governments, and enterprise customers. As testing demand normalized, the company pivoted toward higher-value diagnostics, precision medicine, and advanced testing modalities rather than chasing volume alone.
That same period also prompted a reassessment of organizational structure. While diagnostics and clinical development served the same life sciences ecosystem, their capital intensity, operating rhythms, and risk profiles increasingly diverged. In 2023, Labcorp spun off the late-stage clinical development operations of the legacy Covance business into a new, independent public company called Fortrea – while retaining early development capabilities within Labcorp Drug Development. These retained operations include preclinical research, translational medicine, and central laboratory services that remain tightly linked to Labcorp’s diagnostics, biomarkers, and data assets. In effect, the most capital-intensive, execution-heavy CRO activities were separated, while LH kept the components that naturally integrate with its laboratory and data platform. The separation marked an evolution of the earlier integration strategy – moving from scale-building under one roof to sharper accountability, capital discipline, and execution clarity across distinct businesses.
Since then, Labcorp has leaned into partnerships and technology to reinforce its leadership. Collaborations with health systems and biopharma companies have expanded access to specialized testing and real-world evidence capabilities, while investments in digital pathology, data integration, and AI-assisted workflows have modernized how laboratory insights are delivered and scaled. Select acquisitions and laboratory asset deals have further strengthened geographic reach and testing depth without diluting focus.
From a regional lab operator to a central node in global healthcare infrastructure, Labcorp’s history is defined by adaptation. Its recent chapter reflects a company that has refined its scope without abandoning its ambition, modernized its platform, and positioned itself for durable leadership in an increasingly data-driven healthcare system.
1
Diagnosing Scale
Labcorp operates as a core utility of modern healthcare – a company incorporated at the very core of the medical value chain, supporting clinical decisions, drug development, and preventive care by translating biological data into actionable insight at an industrial scale. Its business is built around two tightly linked platforms: a nationwide diagnostics network that supports everyday medical care, and a global laboratory infrastructure that underpins pharmaceutical and biotechnology research. Together, these platforms allow LH to grow not by chasing episodic demand, but by embedding itself deeper into how medicine is practiced and advanced.
The Diagnostics business remains the backbone, accounting for roughly 75% of total revenue. This franchise spans routine testing, specialty diagnostics, and an expanding suite of high-complexity tests used in oncology, neurology, autoimmune disease, and women’s health. Growth here is no longer tied to pandemic-era distortions. Instead, it reflects structurally higher utilization, an aging and more chronically ill population, and a steady increase in test complexity. Management has been explicit that utilization today is not a post-COVID catch-up effect, but a reset to a higher baseline driven by demographics and disease prevalence.
Within Diagnostics, LH has deliberately tilted its mix toward specialty testing. Oncology is the clearest example. The integration of Invitae1 accelerated Labcorp’s capabilities in molecular diagnostics and enabled the rapid rollout of minimal residual disease liquid biopsy tests across breast, lung, and colon cancer. These tests sit at the intersection of diagnostics and treatment selection, reinforcing Labcorp’s role in precision medicine rather than commodity testing. Neurology represents a parallel opportunity. Beyond Alzheimer’s disease, Labcorp is building a broad neurology testing portfolio designed to support diagnosis, monitoring, and emerging therapies, with the scale to run companion and follow-on tests alongside any single biomarker.
Growth is also reinforced structurally through health system partnerships. Labcorp increasingly manages hospital laboratories and acquires outreach assets, expanding access points while lowering system-wide costs for payers and providers. These deals deepen market share, improve routing efficiency, and strengthen payer relationships, allowing pricing to remain stable even as volumes grow. Regional lab consolidation and targeted acquisitions further densify the network without diluting focus.
The second platform – Biopharma Laboratory Services (BLS) – contributes roughly 25% of revenue and provides a longer-duration growth engine. Within BLS, Central Laboratory Services (CLS) is the dominant operating component and is distinct from clinical trial execution. CLS does not run trials; instead, it provides the laboratory infrastructure that supports Phase II and Phase III studies, including sample analysis, biomarker testing, logistics, and regulatory-grade data generation. Demand here is anchored by large pharmaceutical companies and late-stage development programs that continue to require centralized lab support even when sponsors reduce or delay trial operations in funding downturns. Scale matters in this model. Labcorp’s central labs benefit from shared infrastructure, deep specialty testing expertise, and tight data integration with its diagnostics business. Long-term investments such as the new Indiana central lab campus reflect confidence in sustained demand for centralized laboratory support across global clinical research, rather than exposure to short-cycle CRO-style execution work.
Technology increasingly binds these businesses together. Digital pathology, AI-assisted workflows, and automation are reshaping how tests are ordered, processed, and interpreted. AI tools such as Test Finder simplify clinical decision-making, while backend automation improves capacity utilization, turnaround times, and cost efficiency. Consumer-facing diagnostics and functional health testing add optionality, expanding access and prevention-focused use cases without becoming a strategic distraction.
How Labcorp grows is as important as what it does. Management remains disciplined, prioritizing acquisitions that are accretive, fast to integrate, and aligned with existing platforms. Portfolio pruning in early development and device testing reflects the same philosophy – focusing capital and attention on areas where scale, data, and integration reinforce long-term advantage. The result is a business that grows not by volume alone, but by becoming more central to the healthcare system it serves.
—
1 – Invitae was a genetic testing company focused on oncology and inherited disease diagnostics. Following its bankruptcy in 2024, Labcorp acquired select Invitae assets, including molecular testing platforms, intellectual property, and scientific capabilities, which have since been fully integrated into Labcorp Diagnostics and used to expand its oncology and minimal residual disease test portfolio.
—
1
Clinically Proven
Labcorp’s third quarter of 2025 marked a clean inflection point from post-pandemic normalization to steady, execution-driven growth. Revenue rose 8.6% year-over-year to $3.6 billion, extending the company’s streak to at least eight consecutive quarterly revenue beats. Adjusted EPS climbed 19% year-over-year to $4.18, representing the ninth straight quarter of earnings outperformance and reflecting both volume momentum and operating leverage across the core business. Free cash flow reached roughly $280 million in the quarter, up sharply from the prior year, underscoring improved working-capital efficiency and disciplined cost control.
The composition of growth matters as much as the headline numbers. Diagnostics revenue increased 8.5% year-over-year, with organic growth of just over 6%, driven by higher utilization, rising test-per-accession, and continued mix shift toward specialty diagnostics. Management has been explicit that the underlying strength in diagnostic demand is a long-term trend rather than a temporary spike, a view reinforced by consistent growth across routine and higher-complexity testing rather than reliance on any single category. The BLS segment grew 8.3% year-over-year, with CLS up approximately 10%, offsetting softness in early development activity tied to delayed study starts among smaller biotechs.
Profitability continued to improve. Enterprise operating margin expanded by roughly 100 basis points year-over-year, with Diagnostics margins up about 110 basis points and BLS margins modestly higher. These gains reflect the cumulative impact of the LaunchPad efficiency initiative,2 Invitae integration synergies, and a more favorable revenue mix. Over the past several quarters, Labcorp has consistently converted mid-single-digit organic growth into faster earnings growth, signaling a structurally stronger margin profile than in the immediate post-COVID period.
Balance-sheet fundamentals provide an important anchor as Labcorp enters its next planning cycle. At the end of Q3 2025, gross leverage stood at roughly 2.4x trailing adjusted EBITDA, below the company’s stated target range of 2.5-3.0x. This conservative positioning gives Labcorp flexibility to navigate policy uncertainty, continue disciplined tuck-in acquisitions, and sustain investment in automation, specialty testing, and laboratory infrastructure without stretching the balance sheet. Strong free cash flow generation remains central to that equation.
One external variable affecting forward expectations is PAMA reimbursement. The Protecting Access to Medicare Act is a long-standing policy framework that periodically resets Medicare pricing for common laboratory tests based on reported private-market rates. In practice, the data used to set those rates has been widely criticized as incomplete, leading Congress to delay implementation multiple times over concerns about access to testing and system stability. While the industry is pushing for PAMA reform, as of late January 2026, further reimbursement cuts are scheduled to resume unless legislative action intervenes again. LH has conservatively modeled a potential gross impact of roughly $100 million on revenue and earnings if the cuts take full effect, while already identifying $25-30 million of mitigation through operational efficiencies, mix shift toward higher-value testing, and pricing discipline. This remains an industry-wide policy headwind rather than a company-specific execution issue, and one that has been visible and debated for several years.
Against that backdrop, management’s updated guidance for 2025 reflects steady confidence. Full-year revenue is now expected to grow 7.4-8.0%, with the midpoint trimmed modestly due to foreign exchange and acquisition timing rather than underlying demand. Adjusted EPS guidance was raised to $16.15-16.50, implying roughly 12% year-over-year growth at the midpoint. Free cash flow expectations were also increased to $1.17-1.29 billion, reinforcing Labcorp’s capacity to fund investment, manage leverage, and return capital.
Looking ahead, analysts expect Q4 2025 to extend the pattern of year-over-year revenue growth and stable margins, with seasonal effects offset by specialty diagnostics momentum and sustained strength in CLS. Consensus expectations remain slightly below management’s updated full-year EPS range, leaving room for modest upside if execution remains consistent. For 2026, while formal guidance will be set with the Q4 earnings release, both management commentary and analyst models assume continued mid-single-digit organic growth, incremental margin support from LaunchPad initiatives, and durable free cash flow generation – with PAMA outcomes influencing the degree of upside rather than the underlying direction of the business. Taken together, recent results point to a business operating from a more stable earnings base, supported by scale, mix, and disciplined execution.
—
2 – LaunchPad is Labcorp’s ongoing operational efficiency program focused on process redesign, automation, and technology-driven productivity gains across laboratory operations, logistics, and administrative functions. The initiative targets recurring cost savings to offset wage inflation and support margin expansion, with recent progress increasingly driven by automation, digital workflows, and AI-enabled process improvements rather than one-time actions.
—
1
Multiple Choice
Labcorp’s most relevant peers sit within healthcare services infrastructure rather than across the broader life sciences tools universe. Quest Diagnostics stands as the closest direct comparison, sharing Labcorp’s national clinical laboratory footprint, reimbursement exposure, and focus on scale-driven diagnostics. Charles River Laboratories adds a complementary lens on biopharma laboratory services, reflecting valuation and cycle dynamics tied to drug development activity rather than routine medical utilization. IQVIA rounds out the group as a broader reference point for outsourced biopharma services, offering context on how the market values data- and research-driven platforms adjacent to Labcorp’s central laboratory operations. Together, these peers frame the environment in which Labcorp’s scale, mix, and execution discipline are assessed by the market.
Over the past year, stock performance across Labcorp’s peer set has diverged meaningfully, reflecting differences in cycle positioning and narrative clarity rather than execution quality alone. Charles River delivered the strongest gains, rising more than 30%, as investors re-rated the stock on signs that preclinical demand had stabilized and that earnings had likely troughed – a classic recovery trade following a period of compressed expectations. Quest Diagnostics advanced in the mid-teens, benefiting from its simpler structure and perception as a steady, low-drama compounder with fewer unresolved policy or portfolio questions. IQVIA posted similar gains, supported by its positioning as a data- and services-driven biopharma platform, which insulated the stock from near-term reimbursement noise. Labcorp, by contrast, lagged with a ~7% return despite consistent earnings beats, margin expansion, and raised guidance. The gap reflects a lingering overhang rather than weak fundamentals: uncertainty around PAMA reimbursement, ongoing portfolio reshaping, and higher perceived complexity have capped multiple expansion. In practice, peers were rewarded for either clarity or recovery, while Labcorp continues to be priced for durability – with the market waiting for remaining sources of uncertainty to clear.
That hesitation carries a valuation cost. While hesitancy is understandable, it could lead to missing the current valuation levels, as re-rating could happen virtually overnight if a strong enough catalyst appears, such as if LH produces better-than-expected results at its next earnings release in three weeks. Meanwhile, the company’s valuation multiples are extremely attractive – both compared to the peer group and to the broadly inexpensive Healthcare sector medians. Labcorp trades at a discount to the sector on most metrics, with the gap most visible across sales-based ratios such as trailing and forward EV/Sales and Price/Sales, which point to underpriced scale rather than deteriorating fundamentals. The market is not yet fully valuing the company’s embedded infrastructure – its national diagnostics network and global central lab platform – as a durable, quasi-utility asset. While the discount versus peers on these ratios is not as striking, it is still noticeable. Moreover, LH trades below peer averages on all other key metrics, including trailing and forward P/E and EV/EBITDA, TTM Price/Cash Flow, and forward PEG. Taken together, the picture is one of quality, scale, and solid growth at a reasonable price – a rare setup in today’s market.
Labcorp employs a balanced capital return strategy focused on returning cash to shareholders through a combination of dividends and share repurchases, while prioritizing investments in growth and maintaining a strong balance sheet. This approach has been in place since early 2022, following the company’s spin-off of Fortrea and a review of capital allocation priorities. Dividends come first and are intentionally conservative, with a yield of 1.14%, while non-negligible, still below the sector average. For LH, the dividend is a baseline commitment, not a signaling tool – meant to remain secure across reimbursement cycles, policy uncertainty, and acquisition phases.
Share repurchases are the flexible component. Buybacks are used to offset dilution, enhance EPS growth, and return excess capital when shares are viewed as undervalued. Following the Fortrea spin-off, Labcorp received roughly $1.6 billion in proceeds, part of which has been directed toward share repurchases, reinforcing that capital returns are funded by real balance-sheet events, not financial engineering. In 2025, the company was active but selective, forgoing buybacks in Q1, then repurchasing $200 million in Q2, but scaling back to $25 million in Q3 as the focus shifted toward acquisitions. That discipline matters because it keeps Labcorp positioned for upside without forcing the market’s hand. Capital is being returned when it is genuinely in excess, withheld when strategic opportunities appear, and preserved to absorb policy noise without compromising growth.
If valuation gaps close through clarity rather than multiple expansion alone – whether via continued earnings delivery, easing policy uncertainty, or a simpler portfolio narrative – Labcorp does not need a reinvention to rerate: it needs recognition. At current levels, the stock reflects durability without crediting optionality. That imbalance increasingly favors patience, especially for a business whose scale, cash generation, and execution have already been clinically proven.
1
Investing Takeaway
Labcorp offers a rare blend of durability and optional upside within healthcare services. It operates at the core of medical decision-making, translating biological data into insight across routine care, specialty diagnostics, and drug development. The company has emerged from post-pandemic normalization with a clearer business mix, stronger margins, and a sharper strategic focus on areas where scale and data matter most. Its national diagnostics network provides stability and recurring demand, while its global laboratory infrastructure supports innovation in precision medicine and clinical research. Disciplined capital allocation reinforces this foundation, balancing reinvestment, resilience, and shareholder returns. With execution steady and remaining uncertainties increasingly defined, Labcorp stands positioned for reappraisal. For investors seeking a high-quality compounder embedded in essential healthcare workflows, this is a case that is less about reinvention and more about recognition.
1
1
New Sell: Capital One Financial (COF)
We are exiting Capital One at this stage, not because the franchise is broken, but because the balance between execution risk and strategic ambition has shifted unfavorably.
On the surface, Q4 2025 results showed continued top-line momentum. Revenue exceeded expectations, liquidity remained strong, and capital ratios stayed comfortably above regulatory minimums. Credit trends continue to normalize year-over-year, and management reiterated confidence in long-term earnings power following the Discover acquisition. From a balance-sheet and market-position standpoint, COF remains a formidable operator.
The problem lies beneath the headline numbers – specifically in cost discipline, integration complexity, and strategic focus.
The quarter exposed a meaningful deterioration in operating efficiency. A significantly higher-than-expected efficiency ratio signaled that expenses are now running ahead of revenue growth, driven by elevated marketing spend, integration costs, and technology investment. At the same time, adjusted earnings missed consensus expectations, breaking the perception that Capital One could absorb integration complexity without near-term profitability pressure. This matters because the Discover transaction is still being digested, and investors were looking for confirmation that cost control would improve as scale benefits materialized. Instead, the opposite occurred.
Against this backdrop, the announcement of the $5.15 billion Brex acquisition further complicates the story. Strategically, the deal makes sense on paper. Brex accelerates Capital One’s push into corporate payments, expense management, and software-enabled financial services – areas with higher long-term growth and stickier customer relationships.
However, timing matters. Launching a second major integration while still processing a transformative Discover deal introduces execution risk that is difficult to ignore, particularly for a regulated financial institution rather than a venture-style fintech.
There is also a capital allocation signal embedded in the decision. Brex is expected to be initially earnings-dilutive and to consume capital, even as operating efficiency is under pressure. While management insists buybacks will continue, the combination of higher expenses, integration demands, and capital absorption raises legitimate questions about the pace and flexibility of shareholder returns over the next several quarters.
This is not a call on credit quality or solvency. It is a judgment about complexity and strategic overreach. COF is asking investors to underwrite two large integrations, rising cost intensity, and a pivot toward fintech-style growth – all at once. That may ultimately work, but it shifts the risk profile away from what we want at this point in the cycle.
We are selling COF to protect capital and avoid a period where execution risk dominates the narrative. Capital One remains a high-quality franchise, and if efficiency stabilizes, integration risk subsides, and capital returns regain clarity, we would be open to revisiting the name. For now, discipline outweighs optimism.
1
1
Smart Investor’s Winners Club
The Winners Club represents stocks from the Smart Investor Portfolio that have risen at least 30% since their purchase dates.
AI trade regained momentum, and CSCO returned to the Club, expanding the ranks to 19 stocks: GE, AVGO, ANET, APH, TSM, EME, HWM, IBKR, PH, ORCL, GOOGL, VRT, MTZ, RTX, CRWD, BK, MS, IBM, and CSCO.
The first contender for the Club’s entry is now ASX with a 29.23% gain since we purchased it just a month ago, on December 24. Will it join the ranks, or will another stock outrun it to the finish line?
1
1
|
